Government subsidies must directly underwrite obesity therapies to sustain patient access when commercial insurance fails.
Because soaring metabolic drug demand forces employer-sponsored health plans to restrict coverage, state and federal safety nets must step in to directly finance and guarantee affordable patient access.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
In response to rising costs and limited commercial coverage, the federal government launched a dedicated Medicare bridge program to subsidize weight-loss drug access.
Skyrocketing pharmacy costs are driving employers to restrict or entirely drop commercial insurance coverage for metabolic weight-loss medications.
It demonstrates how rising costs force employer-sponsored and public employee health plans to restrict GLP-1 coverage, increasing the need for safety nets.
Delayed commercial Part D participation forces the federal government to directly subsidize and extend access under a taxpayer-funded bridge.
The launch of the Medicare GLP-1 Bridge program illustrates a federal safety net directly financing treatment to guarantee senior patient access.
Achieving cost-neutrality under MFN pricing models provides a powerful argument for federal programs to underwrite and subsidize these therapies.